Natera, Inc. (NTRA): Price and Financial Metrics
GET POWR RATINGS... FREE!
NTRA POWR Grades
- NTRA scores best on the Stability dimension, with a Stability rank ahead of 34.21% of US stocks.
- NTRA's strongest trending metric is Momentum; it's been moving down over the last 52 weeks.
- NTRA ranks lowest in Momentum; there it ranks in the 11th percentile.
NTRA Stock Summary
- With a price/sales ratio of 16.09, Natera Inc has a higher such ratio than 88.89% of stocks in our set.
- Over the past twelve months, NTRA has reported earnings growth of 126.33%, putting it ahead of 83.54% of US stocks in our set.
- Revenue growth over the past 12 months for Natera Inc comes in at 56.09%, a number that bests 86.86% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to Natera Inc are OM, LSPD, EXAS, ACCD, and AMWL.
- Visit NTRA's SEC page to see the company's official filings. To visit the company's web site, go to www.natera.com.
NTRA Valuation Summary
- NTRA's price/sales ratio is 22; this is 93.83% higher than that of the median Healthcare stock.
- Over the past 75 months, NTRA's price/sales ratio has gone up 15.1.
- NTRA's EV/EBIT ratio has moved up 1076.2 over the prior 75 months.
Below are key valuation metrics over time for NTRA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| NTRA | 2021-08-31 | 22.0 | 37.1 | -35.3 | -37.9 |
| NTRA | 2021-08-30 | 22.3 | 37.6 | -35.7 | -38.3 |
| NTRA | 2021-08-27 | 21.9 | 37.0 | -35.2 | -37.8 |
| NTRA | 2021-08-26 | 21.4 | 36.0 | -34.3 | -36.8 |
| NTRA | 2021-08-25 | 21.4 | 36.1 | -34.3 | -36.9 |
| NTRA | 2021-08-24 | 21.3 | 36.0 | -34.2 | -36.8 |
NTRA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- NTRA has a Quality Grade of D, ranking ahead of 16.91% of graded US stocks.
- NTRA's asset turnover comes in at 0.553 -- ranking 46th of 81 Healthcare stocks.
- CHE, USPH, and VCYT are the stocks whose asset turnover ratios are most correlated with NTRA.
The table below shows NTRA's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.553 | 0.496 | -0.316 |
| 2021-03-31 | 0.510 | 0.498 | -0.272 |
| 2020-12-31 | 0.490 | 0.479 | -0.286 |
| 2020-09-30 | 0.509 | 0.480 | -0.277 |
| 2020-06-30 | 0.609 | 0.472 | -0.279 |
| 2020-03-31 | 0.692 | 0.462 | -0.273 |
NTRA Price Target
For more insight on analysts targets of NTRA, see our NTRA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $150.11 | Average Broker Recommendation | 1.35 (Strong Buy) |
NTRA Stock Price Chart Interactive Chart >
NTRA Price/Volume Stats
| Current price | $94.66 | 52-week high | $129.09 |
| Prev. close | $96.10 | 52-week low | $83.19 |
| Day low | $93.71 | Volume | 719,600 |
| Day high | $99.63 | Avg. volume | 875,127 |
| 50-day MA | $112.50 | Dividend yield | N/A |
| 200-day MA | $108.68 | Market Cap | 8.95B |
Natera, Inc. (NTRA) Company Bio
Natera Inc. is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The company was founded in 2003 and is based in San Carlos, California.
Latest NTRA News From Around the Web
Below are the latest news stories about Natera Inc that investors may wish to consider to help them evaluate NTRA as an investment opportunity.
Natera's Panorama SMART Study Results Accepted for Publication by the American Journal of Obstetrics and Gynecology (AJOG)Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, announced that the first manuscript from the landmark SMART study has been accepted for publication by the American Journal of Obstetrics and Gynecology (AJOG). This publication describes the performance of the Panorama non-invasive prenatal test (NIPT) for common trisomies. |
7 Stocks to Buy in November in Light of Their October DipOctober was a good month in the markets. |
Notable Natera Insider Makes $2.8M SaleBurkes Michael Brophy, Insider at Natera (NASDAQ:NTRA), made a large insider sell on November 10, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Brophy sold 25,495 shares of Natera at prices ranging from $110.98 to $112.62. The total transaction amounted to $2,833,421. Following the transaction, Brophy still owns 58,588 shares of the company, worth $6,746,994. Natera shares are trading up 0.1% at $115.16 at |
Natera, Inc. (NASDAQ:NTRA) Receives $141.00 Consensus Target Price from AnalystsNatera, Inc. (NASDAQ:NTRA) has received a consensus rating of Buy from the thirteen ratings firms that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued ratings [] |
Y Intercept Hong Kong Ltd Invests $1.15 Million in Natera, Inc. (NASDAQ:NTRA)Y Intercept Hong Kong Ltd bought a new position in Natera, Inc. (NASDAQ:NTRA) during the second quarter, according to its most recent 13F filing with the SEC. The fund bought 10,113 shares of the medical research companys stock, valued at approximately $1,148,000. Several other institutional investors have also bought and sold shares of the company. [] |
NTRA Price Returns
| 1-mo | -19.23% |
| 3-mo | -19.76% |
| 6-mo | N/A |
| 1-year | 7.41% |
| 3-year | 444.96% |
| 5-year | 688.83% |
| YTD | -4.88% |
| 2020 | 195.40% |
| 2019 | 141.33% |
| 2018 | 55.28% |
| 2017 | -23.23% |
| 2016 | 8.43% |
Continue Researching NTRA
Here are a few links from around the web to help you further your research on Natera Inc's stock as an investment opportunity:Natera Inc (NTRA) Stock Price | Nasdaq
Natera Inc (NTRA) Stock Quote, History and News - Yahoo Finance
Natera Inc (NTRA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...